Open access
Study design of the phase III ADELA trial of elacestrant with or without everolimus in ESR1-mutated ER+/HER2- advanced breast cancer after progression on endocrine therapy plus a CDK4/6 inhibitor.
J. Pérez-García
A. Llombart-Cussac
E. López-Miranda
A. Cortés
I. García
Elena Galve Calvo
M. Ruíz Borrego
A. Cochs
Antonia Perelló Martorell
S. Morales
Laia Boronat Ruiz
S. Marín-Liébana
C. Saavedra
I. Blancas
C. Hinojo
M. López Flores
S. Ladoire
P. Schmid
G. Freyer
Rui-Rui Zhang
D. Alcalá-López
J. Carvalho-Santos
O. Boix
C. Barrios
Giuseppe Curigliano
R. Bartsch
A. Hardy-Bessard
T. Wasserman
Javier Cortés
Medicine
Abstract
CLINICAL TRIAL REGISTRATION www.clinicaltrials.gov identifier is NCT06382948; EU Clinical Trials identifier is EUCT 2024-512926-27-00.